Therapeutic and Prophylactic Heparin Dosing for Pulmonary Embolism
For therapeutic anticoagulation in pulmonary embolism, administer an initial IV bolus of 5,000 units (or 80 units/kg) followed by continuous infusion of 18 units/kg/hour (typically 20,000-40,000 units/24 hours), adjusted to maintain aPTT at 1.5-2.5 times control or anti-Factor Xa level of 0.3-0.7 units/mL. For prophylaxis in at-risk patients, use 5,000 units subcutaneously every 8-12 hours 1.
Therapeutic Dosing for Acute PE
The FDA-approved regimen for therapeutic anticoagulation consists of 1:
Continuous IV Infusion (Preferred Method)
- Initial bolus: 5,000 units IV push
- Maintenance infusion: 20,000-40,000 units per 24 hours (approximately 18 units/kg/hour for a 68 kg patient)
- Target: aPTT 1.5-2.5 times control or anti-Factor Xa 0.3-0.7 units/mL
Alternative: Intermittent IV Injection
- Initial dose: 10,000 units IV
- Maintenance: 5,000-10,000 units every 4-6 hours
Alternative: Subcutaneous Administration
- Initial dose: 5,000 units IV bolus, followed by 10,000-20,000 units subcutaneously
- Maintenance: 8,000-10,000 units every 8 hours OR 15,000-20,000 units every 12 hours
Monitoring Requirements
Check aPTT at baseline, then approximately every 4 hours during initiation until therapeutic range is achieved 1. The 2019 ESC guidelines emphasize that therapeutic anticoagulation must be administered for >3 months to all PE patients 2. Recent evidence shows that achieving therapeutic anticoagulation rapidly (median 9.13 hours to first therapeutic anti-Factor Xa) correlates with excellent outcomes, with only 1% recurrent thromboembolism and 6.2% mortality 3.
Critical caveat: A subtherapeutic initial anti-Factor Xa level (<0.3 units/mL) is associated with significantly increased mortality risk (27.78% vs 8.05%, p=0.021) 3. Historical data confirms that failure to achieve adequate anticoagulation (aPTT >1.5 times control) results in a 25% risk of recurrent venous thromboembolism 4.
Monitoring Parameters
- aPTT: Target 60-85 seconds (1.5-2.5 times baseline)
- Anti-Factor Xa: Target 0.3-0.7 units/mL (increasingly preferred as more accurate) 3
- Platelet count: Monitor regularly for heparin-induced thrombocytopenia
- Hematocrit and occult blood: Throughout therapy
Prophylactic Dosing
For prevention of postoperative thromboembolism, administer 5,000 units subcutaneously 2 hours before surgery, then 5,000 units every 8-12 hours for 7 days or until fully ambulatory 1.
The prophylactic regimen is indicated for:
- Major abdominothoracic surgery patients
- Patients at risk for thromboembolic disease
- General surgery, gynecology, urology procedures
Important distinction: Prophylactic dosing (5,000 units every 8-12 hours) reduces DVT incidence from approximately 30% to 7.5-10% in general surgery 5. The higher frequency (every 8 hours vs every 12 hours) provides superior protection and is the only regimen proven to reduce fatal postoperative pulmonary emboli 5.
Special Populations
Pediatric Dosing
- Initial bolus: 75-100 units/kg IV over 10 minutes
- Maintenance:
- Infants <2 months: 28 units/kg/hour (highest requirements)
- Infants: 25-30 units/kg/hour
- Children >1 year: 18-20 units/kg/hour
- Target: aPTT 60-85 seconds 1
Morbidly Obese Patients
Standard weight-based protocols with maximum dose caps can cause dangerous delays in achieving therapeutic anticoagulation 6. Use adjusted dosing weight: IBW + 0.3(ABW - IBW) or IBW + 0.4(ABW - IBW) rather than actual body weight to avoid both underdosing and excessive delays 6.
Duration of Therapy
According to 2019 ESC guidelines 2:
- Minimum 3 months for all PE patients
- Discontinue after 3 months if first PE with major transient/reversible risk factor
- Indefinite anticoagulation for recurrent VTE not related to reversible factors
- Transition to oral anticoagulation after 7-10 days of heparin, overlapping until INR therapeutic for warfarin 1
Critical Pitfalls to Avoid
Do NOT use 1 mL heparin vials interchangeably - fatal medication errors have occurred confusing therapeutic vials with catheter lock flush vials 1
Do NOT use intramuscular route - high risk of hematoma formation 1
Do NOT delay achieving therapeutic levels - subtherapeutic anticoagulation in first 24 hours dramatically increases recurrence risk 4, 3
Invert infusion bags at least 6 times when adding heparin to prevent pooling and ensure adequate mixing 1
For subcutaneous prophylaxis, use deep intrafat injection (above iliac crest or abdominal fat layer) with 25-26 gauge needle, rotating sites 1